These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 34147649)

  • 1. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.
    García-Grimshaw M; Ceballos-Liceaga SE; Hernández-Vanegas LE; Núñez I; Hernández-Valdivia N; Carrillo-García DA; Michel-Chávez A; Galnares-Olalde JA; Carbajal-Sandoval G; Del Mar Saniger-Alba M; Carrillo-Mezo RA; Fragoso-Saavedra S; Espino-Ojeda A; Blaisdell-Vidal C; Mosqueda-Gómez JL; Sierra-Madero J; Pérez-Padilla R; Alomía-Zegarra JL; López-Gatell H; Díaz-Ortega JL; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Clin Immunol; 2021 Aug; 229():108786. PubMed ID: 34147649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.
    López-Mena D; García-Grimshaw M; Saldivar-Dávila S; Hernandez-Vanegas LE; Saniger-Alba MDM; Gutiérrez-Romero A; Carrillo-Mezo R; Valdez-Ruvalcaba HE; Cano-Nigenda V; Flores-Silva FD; Cantú-Brito C; Santibañez-Copado AM; Diaz-Ortega JL; Ceballos-Liceaga SE; Murillo-Bonilla LM; Sepulveda-Núñez AI; García-Talavera V; Gonzalez-Guerra E; Cortes-Alcala R; Lopez-Gatell H; Carbajal-Sandoval G; Reyes-Terán G; Valdés-Ferrer SI; Arauz A
    Neurology; 2022 May; 98(19):e1933-e1941. PubMed ID: 35277439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program.
    Toledo-Salinas C; Scheffler-Mendoza SC; Castano-Jaramillo LM; Ortega-Martell JA; Del Rio-Navarro BE; Santibáñez-Copado AM; Díaz-Ortega JL; Baptista-Rosas R; Sánchez-Novoa P; García-Grimshaw M; Valdés-Ferrer SI; Reyes-Terán G; Mendoza-Hernández DA
    J Clin Immunol; 2022 Nov; 42(8):1593-1599. PubMed ID: 35976470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seizures following COVID-19 vaccination in Mexico: A nationwide observational study.
    Núñez I; García-Grimshaw M; Castillo Valencia CY; Aguilera Callejas DE; Moya Alfaro ML; Saniger-Alba MDM; Gutiérrez-Romero A; Carrillo-Mezo R; Ceballos-Liceaga SE; Baptista-Rosas RC; López-Gatell H; Reyes-Terán G; Díaz-Ortega JL; Arauz A; Valdés-Ferrer SI; Hernández-Vanegas LE
    Epilepsia; 2022 Oct; 63(10):e144-e149. PubMed ID: 35943891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
    García-Grimshaw M; Ceballos-Liceaga SE; Michel-Chávez A; García-Alanis M; Cadena-Fernández A; Galnares-Olalde JA; Carbajal-Sandoval G; Carrillo-García DA; Hernández-Valdivia N; Hernández-Vanegas LE; Saniger-Alba MDM; Gutierrez-Romero A; Díaz-Ortega JL; Reyes-Terán G; López-Gatell H; Flores-Silva FD; Cantú-Brito C; Chiquete E; Arauz A; Valdés-Ferrer SI
    Vaccine; 2021 Nov; 39(48):6975-6979. PubMed ID: 34742595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.
    García-Grimshaw M; Michel-Chávez A; Vera-Zertuche JM; Galnares-Olalde JA; Hernández-Vanegas LE; Figueroa-Cucurachi M; Paredes-Ceballos O; Reyes-Terán G; Carbajal-Sandoval G; Ceballos-Liceaga SE; Arauz A; Valdés-Ferrer SI
    Clin Immunol; 2021 Sep; 230():108818. PubMed ID: 34358692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
    Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
    Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
    Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up.
    Ponticelli D; Madotto F; Conti S; Antonazzo IC; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P; Mantovani LG
    Intern Emerg Med; 2022 Mar; 17(2):481-486. PubMed ID: 34637084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
    Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
    J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
    Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
    JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
    Dagan N; Barda N; Biron-Shental T; Makov-Assif M; Key C; Kohane IS; Hernán MA; Lipsitch M; Hernandez-Diaz S; Reis BY; Balicer RD
    Nat Med; 2021 Oct; 27(10):1693-1695. PubMed ID: 34493859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais.
    Silva RBD; Silva TPRD; Sato APS; Lana FCF; Gusmão JD; Souza JFA; Matozinhos FP
    Rev Saude Publica; 2021; 55():66. PubMed ID: 34706042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.
    Spinelli FR; Favalli EG; Garufi C; Cornalba M; Colafrancesco S; Conti F; Caporali R
    Arthritis Res Ther; 2022 Jan; 24(1):21. PubMed ID: 35016701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients.
    Havlin J; Svorcova M; Dvorackova E; Lastovicka J; Lischke R; Kalina T; Hubacek P
    J Heart Lung Transplant; 2021 Aug; 40(8):754-758. PubMed ID: 34120839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.